Efavirenz Causes Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Endothelial Cells
Tóm tắt
The non-nucleoside reverse transcriptase inhibitor efavirenz is a widely prescribed antiretroviral drug used in combined antiretroviral therapy. Despite being an essential and life-saving medication, the required lifelong use of HIV drugs has been associated with a variety of adverse effects, including disturbances in lipid metabolism and increased cardiovascular risk. Efavirenz belongs to those HIV drugs for which cardiovascular and endothelial dysfunctions have been reported. It is here shown that elevated concentrations of efavirenz can inhibit endothelial meshwork formation on extracellular matrix gels by normal and immortalized human umbilical vein cells. This inhibition was associated with an increase in oxidative stress markers, endoplasmic reticulum (ER) stress markers, and autophagy. Induction of ER stress occurred at pharmacologically relevant concentrations of efavirenz and resulted in reduced proliferation and cell viability of endothelial cells, which worsened in the presence of elevated efavirenz concentrations. In combination with the HIV protease inhibitor nelfinavir, both oxidative stress and ER stress became elevated in endothelial cells. These data indicate that pharmacologically relevant concentrations of efavirenz can impair cell viability of endothelial cells and that these effects may be aggravated by either elevated concentrations of efavirenz or by a combined use of efavirenz with other oxidative stress-inducing medications.
Tài liệu tham khảo
de Gaetano Donati, K., Rabagliati, R., Iacoviello, L., & Cauda, R. (2004). HIV infection, HAART, and endothelial adhesion molecules: Current perspectives. Lancet Infectious Diseases, 4, 213–222.
Kovari, H., & Weber, R. (2011). Influence of antiretroviral therapy on liver disease. Current Opinion in HIV and AIDS, 6, 272–277.
Calza, L. (2012). Renal toxicity associated with antiretroviral therapy. HIV Clinical Trials, 13, 189–211.
Gresele, P., Falcinelli, E., Sebastiano, M., & Baldelli, F. (2012). Endothelial and platelet function alterations in HIV-infected patients. Thrombosis Research, 129, 301–308.
Fortin, C., & Joly, V. (2004). Efavirenz for HIV-1 infection in adults: An overview. Expert Review on Anti-Infectective Therapy, 25, 671–684.
Best, B. M., & Goicoechea, M. (2008). Efavirenz–still first-line king? Expert Opinion on Drug Metabolism and Toxicology, 4, 965–972.
Maggiolo, F. (2009). Efavirenz: A decade of clinical experience in the treatment of HIV. Journal of Antimicrobial Agents and Chemotherapy, 64, 910–928.
Rakhmanina, N. Y., & van den Anker, J. N. (2010). Efavirenz in the therapy of HIV infection. Expert Opinion on Drug Metabolism and Toxicology, 6, 95–103.
Bumpus, N. N. (2011). Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. Toxicology and Applied Pharmacology, 257, 227–234.
Gomez-Sucerquia, L. J., Blas-Garcia, A., Marti-Cabrera, M., Esplugues, J. V., & Apostolova, N. (2012). Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz. Antiviral Research, 94, 232–241.
Apostolova, N., Gomez-Sucerquia, L. J., Alegre, F., Funes, H. A., Victor, V. M., Barrachina, M. D., et al. (2013). ER stress in human hepatic cells treated with Efavirenz: Mitochondria again. Journal of Hepatology, 59, 780–789.
Gupta, S. K., Shen, C., Moe, S. M., Kamendulis, L. M., Goldman, M., & Dubé, M. P. (2012). Worsening endothelial function with efavirenz compared to protease inhibitors: A 12-month prospective study. PLoS One, 7, e45716.
Mondal, D., Pradhan, L., Ali, M., & Agrawal, K. C. (2004). HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: Exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovascular Toxicology, 43, 287–302.
Jamaluddin, M. S., Lin, P. H., Yao, Q., & Chen, C. (2010). Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells. Atherosclerosis, 208, 104–111.
Edgell, C. J., McDonald, C. C., & Graham, J. B. (1983). Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proceedings of the National Academy of Sciences, USA, 80, 3734–3737.
Brüning, A. (2011). Analysis of nelfinavir-induced endoplasmic reticulum stress. Methods in Enzymology, 491, 127–142.
Arnaoutova, I., George, J., Kleinman, H. K., & Benton, G. (2009). The endothelial cell tube formation assay on basement membrane turns 20: State of the science and the art. Angiogenesis, 12, 267–274.
Aranda, E., & Owen, G. I. (2009). A semi-quantitative assay to screen for angiogenic compounds and compounds with angiogenic potential using the EAhy926 endothelial cell line. Biological Research, 42, 377–389.
Unger, R. E., Krump-Konvalinkova, V., Peters, K., & Kirkpatrick, C. J. (2002). In vitro expression of the endothelial phenotype: Comparative study of primary isolated cells and cell lines, including the novel cell line HPMEC-ST16R. Microvascular Research, 64, 384–397.
Niemann, A., Takatsuki, A., & Elsässer, H. P. (2000). The lysosomotropic agent monodansylcadaverine also acts as a solvent polarity probe. Journal of Histochemistry and Cytochemistry, 48, 251–258.
Gills, J. J., Lopiccolo, J., Tsurutani, J., Shoemaker, R. H., Best, C. J., Abu-Asab, M. S., et al. (2007). Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clinical Cancer Research, 13, 5183–5194.
Ståhle, L., Mober, L., Svensson, J. O., & Sönnerborg, A. (2004). Efavirenz plasma concentrations in HIV-infected patients: Inter- and intraindividual variability and clinical effects. Therapeutic Drug Monitoring, 26, 267–270.
Brüning, A., Gingelmaier, A., Friese, K., & Mylonas, I. (2010). New prospects for nelfinavir in non-HIV-related diseases. Current Molecular Pharmacology, 3, 91–97.
Alfadda, A. A., & Sallam, R. M. (2012). Reactive oxygen species in health and disease. Journal of Biomedicine and Biotechnology, 2012, 936486.
Ryter, S. W., & Choi, A. M. (2013). Regulation of autophagy in oxygen-dependent cellular stress. Current Pharmaceutical Design, 19, 2747–2756.